KR102431418B1 - Rna 치료제를 포함하는 엑소좀 - Google Patents

Rna 치료제를 포함하는 엑소좀 Download PDF

Info

Publication number
KR102431418B1
KR102431418B1 KR1020207016299A KR20207016299A KR102431418B1 KR 102431418 B1 KR102431418 B1 KR 102431418B1 KR 1020207016299 A KR1020207016299 A KR 1020207016299A KR 20207016299 A KR20207016299 A KR 20207016299A KR 102431418 B1 KR102431418 B1 KR 102431418B1
Authority
KR
South Korea
Prior art keywords
leu
lys
glu
val
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020207016299A
Other languages
English (en)
Korean (ko)
Other versions
KR20200086322A (ko
Inventor
로렌조 에리첼리
다누 굽타
저스틴 힌
조엘 노르딘
Original Assignee
에복스 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102431418(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에복스 테라퓨틱스 리미티드 filed Critical 에복스 테라퓨틱스 리미티드
Publication of KR20200086322A publication Critical patent/KR20200086322A/ko
Application granted granted Critical
Publication of KR102431418B1 publication Critical patent/KR102431418B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020207016299A 2017-11-08 2018-11-08 Rna 치료제를 포함하는 엑소좀 Expired - Fee Related KR102431418B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1718471.4A GB2568255A (en) 2017-11-08 2017-11-08 Exosomes comprising RNA therapeutics
GB1718471.4 2017-11-08
PCT/EP2018/080681 WO2019092145A1 (en) 2017-11-08 2018-11-08 Exosomes comprising rna therapeutics

Publications (2)

Publication Number Publication Date
KR20200086322A KR20200086322A (ko) 2020-07-16
KR102431418B1 true KR102431418B1 (ko) 2022-08-16

Family

ID=60664781

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207016299A Expired - Fee Related KR102431418B1 (ko) 2017-11-08 2018-11-08 Rna 치료제를 포함하는 엑소좀

Country Status (18)

Country Link
US (1) US20210369865A1 (cg-RX-API-DMAC7.html)
EP (2) EP3973989A1 (cg-RX-API-DMAC7.html)
JP (2) JP7077404B2 (cg-RX-API-DMAC7.html)
KR (1) KR102431418B1 (cg-RX-API-DMAC7.html)
CN (1) CN111629760B (cg-RX-API-DMAC7.html)
AU (1) AU2018365299B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006960A2 (cg-RX-API-DMAC7.html)
CA (1) CA3082194C (cg-RX-API-DMAC7.html)
DK (1) DK3706796T3 (cg-RX-API-DMAC7.html)
ES (1) ES2899857T3 (cg-RX-API-DMAC7.html)
GB (1) GB2568255A (cg-RX-API-DMAC7.html)
IL (1) IL274125B (cg-RX-API-DMAC7.html)
MX (1) MX389425B (cg-RX-API-DMAC7.html)
PT (1) PT3706796T (cg-RX-API-DMAC7.html)
RU (1) RU2020118554A (cg-RX-API-DMAC7.html)
SG (1) SG11202004199PA (cg-RX-API-DMAC7.html)
WO (1) WO2019092145A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002537B (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019122461A (ja) * 2018-01-12 2019-07-25 株式会社三洋物産 遊技機
JP2019122462A (ja) * 2018-01-12 2019-07-25 株式会社三洋物産 遊技機
JP2019136400A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
JP2019136401A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
JP2019136399A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
JP2019136398A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
FR3081169B1 (fr) * 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
CN108753833B (zh) * 2018-05-28 2021-12-03 上海海洋大学 斑马鱼notch3基因突变体的制备方法
GB201810301D0 (en) * 2018-06-22 2018-08-08 Evox Therapeutics Ltd Combinatorial gene therapy
GB201906482D0 (en) * 2019-05-08 2019-06-19 Evox Therapeutics Ltd Exosome comprising stabilized RNA therapeutics
US20220411785A1 (en) * 2019-11-15 2022-12-29 The University Of Tokyo Library of barcoded extracellular vesicles
CN115176015A (zh) * 2020-02-28 2022-10-11 国立大学法人金泽大学 免疫调节法、免疫调节用核酸组合物及其用途
US20230096378A1 (en) 2020-03-12 2023-03-30 Institute For Basic Science Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition
CN111424017B (zh) * 2020-03-27 2022-08-09 暨南大学 一种装载shRNA的外泌体及其构建方法与应用
WO2021207126A1 (en) * 2020-04-06 2021-10-14 The Trustees Of Dartmouth College Compositions and methods for treating bacterial infections
WO2021223659A1 (en) * 2020-05-06 2021-11-11 Nanjing Iaso Biotherapeutics Co., Ltd. Extracellular vesicles targeting cancer cells and uses thereof
AU2021270587A1 (en) * 2020-05-14 2022-12-08 Modernatx, Inc. LNP compositions comprising an mRNA therapeutic and an effector molecule
CN111647045B (zh) * 2020-06-17 2022-05-27 清华大学深圳国际研究生院 一种cd133拮抗多肽及其衍生物与应用
GB202010278D0 (en) 2020-07-03 2020-08-19 Evox Therapeutics Ltd Extracellular vesicles with improved half-life
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
CN112626068B (zh) * 2020-12-21 2021-12-03 徐州医科大学 一种靶向Notch1基因的LncRNA及其应用
WO2022206781A1 (zh) * 2021-03-30 2022-10-06 南京大学 一种用于治疗结肠炎的rna递送系统
GB202105925D0 (en) 2021-04-26 2021-06-09 Evox Therapeutics Ltd Modified extracellular vesicles (EVs) with improved half-life
EP4364728A4 (en) * 2021-06-30 2025-07-02 Primoris Therapeutics Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING NATURAL OR ARTIFICIAL CELL-DERIVED NANOVESICLES LOADED WITH AN ANTISENSE OLIGONUCLEOTIDE-BASED DRUG
WO2023284380A1 (zh) * 2021-07-15 2023-01-19 呈诺再生医学科技(北京)有限公司 细胞作为基因治疗的载体在临床中的应用
CA3226019A1 (en) 2021-07-20 2023-01-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
US20240360198A1 (en) * 2021-09-01 2024-10-31 National University Corporation Kanazawa University Immunoregulatory method, nucleic acid composition for immunoregulation, and use thereof
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
CN114569721B (zh) * 2022-02-25 2023-03-24 浙江大学 载药的胞外囊泡在制备治疗肥胖或减轻肥胖相关代谢指标的药物中的应用
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
GB202210861D0 (en) * 2022-07-25 2022-09-07 Univ Oxford Innovation Ltd Loaded extracellular vesicle
JP2025535944A (ja) 2022-10-24 2025-10-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ 微細藻類由来の細胞外小胞、鼻腔内投与時のそれらの生体内分布、及びそれらの使用
WO2024112359A1 (en) * 2022-11-21 2024-05-30 The Johns Hopkins University Genetic enhancement of exosome production
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
WO2024194423A1 (en) 2023-03-23 2024-09-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their use for vaccines and for immunomodulation
CN119301256A (zh) * 2023-05-08 2025-01-10 天津外泌体科技有限公司 外囊泡融合蛋白及其应用
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
EP4784736A2 (en) 2023-09-29 2026-08-05 Evox Therapeutics Limited Polypeptides comprising inteins for engineered evs
CN120393034A (zh) * 2023-11-10 2025-08-01 深圳市茵冠生物科技有限公司 一种寡核苷酸偶联物及含其外泌体偶联物与应用
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
WO2025196641A1 (ru) * 2024-03-19 2025-09-25 Биоплатформ Гмбх Гибридные частицы, способ их получения и применение
WO2025247999A1 (en) 2024-05-30 2025-12-04 Conveyxo Method for the production of extracellular vesicles loaded with a molecule of interest and composition comprising such extracellular vesicles
EP4656187A1 (en) 2024-05-30 2025-12-03 ConvEyXo Method for the production of extracellular vesicles loaded with a molecule of interest and composition comprising such extracellular vesicles
WO2026095803A1 (en) 2024-11-04 2026-05-07 Umc Utrecht Holding B.V. Sirna delivery with biological vectors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US20150093433A1 (en) 2013-09-30 2015-04-02 Northwestern University Targeted and modular exosome loading system
WO2017203260A1 (en) 2016-05-25 2017-11-30 Evox Therapeutics Ltd Exosomes comprising therapeutic polypeptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2419144T (pt) 2009-04-17 2019-09-16 Univ Oxford Innovation Ltd Composição para a administração de material genético
CA2798703A1 (en) * 2010-05-10 2011-11-17 The Regents Of The University Of California Endoribonuclease compositions and methods of use thereof
WO2013188638A2 (en) * 2012-06-15 2013-12-19 The Regents Of The University Of California Endoribonucleases and methods of use thereof
CN111206032B (zh) * 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
CA3091771C (en) * 2015-03-13 2026-04-28 The Jackson Laboratory A three-component crispr/cas complex system and uses thereof
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10624849B2 (en) * 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
EP3440090B1 (en) * 2016-04-06 2022-09-28 Ohio State Innovation Foundation Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology
AU2018320864B2 (en) * 2017-08-22 2024-02-22 Napigen, Inc. Organelle genome modification using polynucleotide guided endonuclease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US20150093433A1 (en) 2013-09-30 2015-04-02 Northwestern University Targeted and modular exosome loading system
WO2017203260A1 (en) 2016-05-25 2017-11-30 Evox Therapeutics Ltd Exosomes comprising therapeutic polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Advanced Drug Delivery Reviews. 2013. Vol.65, pp.391-397.

Also Published As

Publication number Publication date
ES2899857T3 (es) 2022-03-15
RU2020118554A3 (cg-RX-API-DMAC7.html) 2022-04-20
AU2018365299A1 (en) 2020-05-28
CN111629760B (zh) 2023-09-05
JP2022113690A (ja) 2022-08-04
DK3706796T3 (da) 2021-11-22
JP2021507682A (ja) 2021-02-25
CA3082194C (en) 2022-10-04
EP3706796A1 (en) 2020-09-16
KR20200086322A (ko) 2020-07-16
CN111629760A (zh) 2020-09-04
EP3706796B1 (en) 2021-09-29
US20210369865A1 (en) 2021-12-02
WO2019092145A1 (en) 2019-05-16
GB201718471D0 (en) 2017-12-20
EP3973989A1 (en) 2022-03-30
CA3082194A1 (en) 2019-05-16
BR112020006960A2 (pt) 2020-10-13
IL274125B (en) 2022-07-01
MX2020004698A (es) 2022-01-17
SG11202004199PA (en) 2020-06-29
IL274125A (en) 2020-06-30
PT3706796T (pt) 2021-11-24
GB2568255A (en) 2019-05-15
AU2018365299B2 (en) 2021-12-16
RU2020118554A (ru) 2021-12-08
MX389425B (es) 2025-03-20
JP7077404B2 (ja) 2022-05-30
ZA202002537B (en) 2022-07-27

Similar Documents

Publication Publication Date Title
AU2018365299B2 (en) Exosomes comprising RNA therapeutics
EP3782646B1 (en) Exosomes comprising therapeutic polypeptides
WO2019238626A1 (en) Engineering extracellular vesicles for affinity purification
EP3965828B1 (en) Exosome comprising stabilized rna therapeutics
EP4561536A1 (en) Loaded extracellular vesicle
HK40065651A (en) Exosomes comprising rna therapeutics
HK40026646B (en) Exosomes comprising rna therapeutics
HK40026646A (en) Exosomes comprising rna therapeutics
HK40042395A (en) Exosomes comprising therapeutic polypeptides
HK40006325B (en) Exosomes comprising therapeutic polypeptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250809

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250809

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250809